Who needs people? That’s most likely what big drug companies are finally realizing after all these years.
Pet vaccines are big business. If you’ve ever taken your pet to a veterinarian, then you know that there are more pet vaccines than ever and vets are not shy in offering them at almost every visit. It seems that no matter what ails your pet, the vet will inquire about the animal’s vaccine status.
A new report is confirming that the business of pet vaccines is becoming explosively profitable; hence, why vets are so darn pushy.
The new report looks into the Veterinary/Animal Vaccines Market and estimates that the market may top $9 billion. For perspective, last January, the current market estimates were $4.4 billion.
The most popular pet vaccines offered are E. coli, rabies, distemper, hepatitis rotavirus, parvovirus, brucellosis, and pinkeye.
The companies used in the estimate include China Animal Husbandry, Tianjin Ringpu, Biogenesis Bago, Hipra, IdtBiologika, Hester, Phibro Animal Health, Vetoquinol, Virbac, Ceva, Boehringer Ingelheim Elanco, Merck Animal Health, and Zoetis.